Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with complicated pleural effusions~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Age \> 18 years~Exclusion Criteria~* Current use of oral anticoagulants (e.g., warfarin sodium) with an International Normalized Ratio (INR) \>5- Activated partial thromboplastin time (aPPT) \> 80, Platelet count \< 100,000/mm3;~* Severe uncontrolled hypertension~* Recognized hypersensitivity to Activase; or any component of its formulation; Traumatic pleural effusion~* Pregnancy (positive pregnancy test)~* In another study for this condition~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Participation in another simultaneous medical investigation~* Recent stroke~* Intracranial hemorrhage~* arteriovenous malformation or aneurysm~* Intracranial neoplasm~* Acute myocardial infarction~* Acute pulmonary embolus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alteplase, Placebo- intapleural instillation (Type: ACTIVE_COMPARATOR): Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
- Placebo, Alteplase -2nd arm (Type: ACTIVE_COMPARATOR): If the first arm fails then the 2nd arm ( cross over to either Placebo or Alteplase not used in the first arm) instilled intrapleurally daily for three days

Based on this trial design, predict the completion outcome and termination type (if applicable).